Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
ID: 337541Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337541
Timeline
    Description

    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for a cooperative agreement titled "Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial organizations to develop innovative engineering solutions addressing significant biomedical challenges, with a focus on establishing robust tools and technologies that meet unmet needs in healthcare. The program encourages multidisciplinary partnerships and requires applicants to outline a strategic plan with specific milestones to achieve their goals within a 5-10 year timeframe. Interested applicants can reach out to Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov for further information. The anticipated application due date is in May 2022, with an estimated award date set for April 1, 2023.

    Point(s) of Contact
    I. George Zubal, Ph.D.
    (301) 827-5168
    igeorge.zubal@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the Blueprint MedTech: Prototype Developer program, aimed at supporting the development of human-grade medical device prototypes. This initiative will utilize the U18 activity code and is designed to assist projects in completing product definition and development, including needs assessment, product design, prototype development, and bench testing, ultimately preparing for first-in-human testing through subsequent FOAs. The program is significant for advancing medical technology and innovation in healthcare, with no cost-sharing or matching requirements. Interested applicants can reach out to Michael Wolfson, Ph.D., at 301-451-6987 or via email at Blueprint-MedTech@nih.gov for further information. The estimated synopsis post date was July 15, 2021, with applications expected to be due in Fall 2021, and the anticipated award date is June 1, 2022.
    Notice of Intent to Publish a Notice of Funding Opportunity for National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a Notice of Funding Opportunity (NOFO) for the National Centers for Biomedical Imaging and Bioengineering (NCBIB), with a focus on advancing research in biomedical imaging and bioengineering. This grant opportunity, identified as P41 Clinical Trials Optional, aims to foster meaningful collaborations and innovative projects within the research community. The anticipated funding amount for this initiative is up to $750,000, with the NOFO expected to be published in late summer 2023 and applications due in fall 2023. Interested applicants should prepare for the estimated project start date of July 30, 2024, and can expect the award announcement by June 30, 2024.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.